X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3393) 3393
Newsletter (110) 110
Book Chapter (13) 13
Dissertation (10) 10
Magazine Article (7) 7
Conference Proceeding (6) 6
Newspaper Article (6) 6
Publication (3) 3
Book / eBook (1) 1
Paper (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
fosfomycin (1791) 1791
humans (1394) 1394
index medicus (1072) 1072
fosfomycin - pharmacology (1004) 1004
anti-bacterial agents - pharmacology (815) 815
microbiology (787) 787
fosfomycin - therapeutic use (613) 613
microbial sensitivity tests (609) 609
pharmacology & pharmacy (605) 605
female (603) 603
infectious diseases (570) 570
male (554) 554
anti-bacterial agents - therapeutic use (491) 491
antibiotics (460) 460
escherichia-coli (397) 397
fosfomycin - administration & dosage (396) 396
animals (391) 391
middle aged (369) 369
adult (364) 364
research (307) 307
aged (304) 304
escherichia coli - drug effects (270) 270
infections (262) 262
urinary tract infections (261) 261
urinary tract infections - drug therapy (260) 260
fosfomycin - analogs & derivatives (251) 251
bacteria (241) 241
resistance (232) 232
biochemical phenomena, metabolism, and nutrition (230) 230
drug resistance in microorganisms (224) 224
drug resistance (219) 219
escherichia coli (212) 212
anti-bacterial agents - administration & dosage (194) 194
drug resistance, bacterial (190) 190
adolescent (188) 188
biochemistry & molecular biology (187) 187
analysis (185) 185
urinary tract infections - microbiology (185) 185
health aspects (184) 184
antimicrobial agents (169) 169
susceptibility (167) 167
drug resistance, microbial (161) 161
drug synergism (161) 161
klebsiella-pneumoniae (157) 157
fosfomycin - metabolism (155) 155
urinary tract infection (154) 154
ciprofloxacin (151) 151
drug therapy, combination (150) 150
biosynthesis (149) 149
enterobacteriaceae (146) 146
fosfomycin - pharmacokinetics (143) 143
nitrofurantoin (142) 142
e coli (138) 138
pseudomonas aeruginosa - drug effects (138) 138
epidemiology (136) 136
treatment outcome (135) 135
enzymes (131) 131
antibiotic resistance (130) 130
child (130) 130
antimicrobial resistance (128) 128
colistin (127) 127
escherichia coli - genetics (127) 127
vancomycin (126) 126
prevalence (124) 124
time factors (123) 123
bacteria - drug effects (120) 120
staphylococcus aureus - drug effects (120) 120
urinary-tract-infections (120) 120
research article (119) 119
drug resistance, multiple, bacterial (118) 118
fosfomycin - chemistry (116) 116
genes (116) 116
escherichia coli infections - drug therapy (115) 115
immunology (110) 110
isoprenoid biosynthesis (110) 110
pathogens (110) 110
staphylococcal infections - drug therapy (110) 110
bacterial infections - drug therapy (109) 109
escherichia coli infections - microbiology (109) 109
kinetics (109) 109
multidrug-resistant (109) 109
pharmacokinetics (109) 109
fosfomycin resistance (106) 106
infection (106) 106
fosfomycin - adverse effects (105) 105
aged, 80 and over (104) 104
escherichia coli - isolation & purification (104) 104
mutation (104) 104
care and treatment (103) 103
identification (102) 102
molecular sequence data (102) 102
physiological aspects (102) 102
tigecycline (102) 102
in-vitro activity (100) 100
administration, oral (99) 99
physical fitness (99) 99
antibacterial agents (98) 98
escherichia coli - enzymology (97) 97
pseudomonas aeruginosa (96) 96
anti-bacterial agents - pharmacokinetics (95) 95
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2980) 2980
Japanese (245) 245
French (159) 159
Italian (90) 90
German (73) 73
Spanish (58) 58
Russian (31) 31
Chinese (20) 20
Turkish (14) 14
Portuguese (7) 7
Bulgarian (5) 5
Polish (4) 4
Dutch (3) 3
Croatian (2) 2
Hungarian (2) 2
Arabic (1) 1
Czech (1) 1
Danish (1) 1
Persian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
International Journal of Antimicrobial Agents, ISSN 0924-8579, 2013, Volume 43, Issue 1, pp. 52 - 59
Abstract Fosfomycin is active in vitro against extensively drug-resistant (XDR) and pandrug-resistant (PDR) Pseudomonas aeruginosa and Klebsiella pneumoniae... 
Infectious Disease | Klebsiella | Pseudomonas | Critically ill | XDR | Fosfomycin | PDR | DEFINITION | MORTALITY | INFECTIOUS DISEASES | COMBINATION THERAPY | MICROBIOLOGY | INTRAVENOUS FOSFOMYCIN | K.-PNEUMONIAE | IMPACT | PREDICTORS | PHARMACOLOGY & PHARMACY | KLEBSIELLA-PNEUMONIAE | ENTEROBACTERIACEAE | Klebsiella pneumoniae - isolation & purification | Pseudomonas aeruginosa - isolation & purification | Klebsiella pneumoniae - drug effects | Prospective Studies | Humans | Middle Aged | Minocycline - analogs & derivatives | Critical Illness | Male | Bacterial Proteins - secretion | Anti-Bacterial Agents - therapeutic use | Drug Therapy, Combination - adverse effects | Minocycline - adverse effects | Minocycline - therapeutic use | Pseudomonas aeruginosa - enzymology | Drug Resistance, Multiple, Bacterial | Aged, 80 and over | Adult | Colistin - therapeutic use | Female | Anti-Bacterial Agents - adverse effects | Colistin - adverse effects | Intensive Care Units | Fosfomycin - therapeutic use | Klebsiella Infections - drug therapy | Pseudomonas Infections - drug therapy | Fosfomycin - adverse effects | Treatment Outcome | Klebsiella Infections - microbiology | Pseudomonas aeruginosa - drug effects | Pseudomonas Infections - microbiology | beta-Lactamases - secretion | Administration, Intravenous | Drug Therapy, Combination - methods | Klebsiella pneumoniae - enzymology | Aged | Care and treatment | Pneumonia | Microbiology | Patient outcomes | Analysis | Bacterial pneumonia | Mortality | Bacteria | Drug resistance
Journal Article
BMC infectious diseases, ISSN 1471-2334, 2018, Volume 18, Issue 1, pp. 626 - 8
BACKGROUND: Febrile Urinary Tract Infection (FUTI) is frequently treated initially with intravenous antibiotics, followed by oral antibiotics guided by... 
Anti-Bacterial Agents/administration & dosage | Double-Blind Method | Administration, Oral | Humans | Middle Aged | Escherichia coli Infections/complications | Fosfomycin/administration & dosage | Escherichia coli/drug effects | Young Adult | Administration, Intravenous | Fever/complications | Urinary Tract Infections/complications | Adolescent | Aged, 80 and over | Placebos | Adult | Female | Aged | Equivalence Trials as Topic | Ciprofloxacin/administration & dosage | INFECTIOUS DISEASES | Randomized clinical trial | ESCHERICHIA-COLI | SUSCEPTIBILITY | GUIDELINES | Antibiotic treatment | Scherichia coli | RESISTANT | Urinary tract infection | THERAPY | PYELONEPHRITIS | LEVOFLOXACIN | Fosfomycin-trometamol | SWITCH | Escherichia coli - drug effects | Fever - complications | Urinary Tract Infections - complications | Anti-Bacterial Agents - adverse effects | Escherichia coli Infections - drug therapy | Ciprofloxacin - adverse effects | Fosfomycin - adverse effects | Urinary Tract Infections - drug therapy | Fosfomycin - administration & dosage | Ciprofloxacin - administration & dosage | Anti-Bacterial Agents - administration & dosage | Fever - drug therapy | Escherichia coli Infections - complications | Drug resistance in microorganisms | Usage | Analysis | Mortality | Urinary tract infections | Chemical properties | Ciprofloxacin | Health aspects | Fosfomycin | Intravenous administration | Clinical trials | Population studies | Systematic review | Infections | Urinary tract | Absenteeism | Drug resistance | Trometamol | Randomization | Pain | E coli | Bacteria | Urogenital system | Electrical impedance | Urine | Women | Bacterial infections | Antimicrobial agents | Patients | Bactericidal activity | Urinary tract diseases | Antibiotics | Internet
Journal Article
Emerging Infectious Diseases, ISSN 1080-6040, 09/2017, Volume 23, Issue 9, pp. 1564 - 1567
FosA, a glutathione S-transferase that inactivates fosfomycin, has been reported as the cause of enzymatic resistance to fosfomycin. We show that multiple... 
ANIMALS | INFECTIOUS DISEASES | FOSA3 | PREVALENCE | IMMUNOLOGY | Prevalence | Foscarnet - pharmacology | Escherichia coli - drug effects | Humans | Fosfomycin - metabolism | Microbial Sensitivity Tests | beta-Lactamases - genetics | Isoenzymes - metabolism | beta-Lactamases - metabolism | Escherichia coli Infections - drug therapy | France - epidemiology | Gene Expression | Escherichia coli - enzymology | Fosfomycin - pharmacology | Isoenzymes - genetics | Escherichia coli Infections - microbiology | Anti-Bacterial Agents - metabolism | Escherichia coli Proteins - metabolism | Plasmids - metabolism | Escherichia coli Infections - epidemiology | Escherichia coli - genetics | Escherichia coli - isolation & purification | Plasmids - chemistry | Escherichia coli Proteins - genetics | Anti-Bacterial Agents - pharmacology | Drug Resistance, Multiple, Bacterial - drug effects | Drug resistance in microorganisms | Urinary tract infections | Beta lactamases | Glutathione transferase | Health aspects | Fosfomycin | bacteria | foodborne infections | Escherichia coli | fosA | Dispatch | acquired resistance | food safety | enteric infectious | Isolates, France | antimicrobial resistance | phosphonoformiate | ESBL | extended spectrum β-lactamase | France | Emergence of Plasmid-Mediated Fosfomycin-Resistance Genes among | fosfomycin
Journal Article
Expert review of anti-infective therapy, ISSN 1744-8336, 2014, Volume 6, Issue 5, pp. 593 - 600
Despite the constantly increasing need for new antimicrobial agents, antibiotic drug discovery and development seem to have greatly decelerated in recent... 
aminoglycoside | Acinetobacter baumannii | multiple-drug resistant | fusidic acid | polymyxin B | Pseudomonas aeruginosa | chloramphenicol | fosfomycin | colistin | Colistin | Aminoglycoside | Fusidic acid | Chloramphenicol | Polymyxin B | Fosfomycin | Multiple-drug resistant | VENTILATOR-ASSOCIATED PNEUMONIA | NATURAL-PRODUCTS | RESISTANT STAPHYLOCOCCUS-AUREUS | ANTIBACTERIAL DRUG DISCOVERY | GRAM-NEGATIVE BACTERIA | INTENSIVE-CARE-UNIT | PSEUDOMONAS-AERUGINOSA | PHARMACOLOGY & PHARMACY | CYSTIC-FIBROSIS | CRITICALLY-ILL PATIENTS | TRIMETHOPRIM-SULFAMETHOXAZOLE | Fusidic Acid - administration & dosage | Humans | Drug Resistance, Bacterial | Drug Utilization | Anti-Bacterial Agents - therapeutic use | Aminoglycosides - administration & dosage | Colistin - therapeutic use | Anti-Bacterial Agents - adverse effects | Colistin - adverse effects | Fosfomycin - therapeutic use | Trimethoprim, Sulfamethoxazole Drug Combination - administration & dosage | Bacterial Infections - drug therapy | Fosfomycin - adverse effects | Colistin - administration & dosage | Fusidic Acid - adverse effects | Chloramphenicol - therapeutic use | Trimethoprim, Sulfamethoxazole Drug Combination - adverse effects | Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use | Fusidic Acid - therapeutic use | Chloramphenicol - adverse effects | Anti-Bacterial Agents - classification | Fosfomycin - administration & dosage | Aminoglycosides - adverse effects | Anti-Bacterial Agents - administration & dosage | Aminoglycosides - therapeutic use | Chloramphenicol - administration & dosage | Drug resistance in microorganisms | Pseudomonas aeruginosa infections | Usage | Antibiotics | Research | Drug therapy | Health aspects | Risk factors | Index Medicus
Journal Article